Pfizer’s Biosimilars Top $2.3bn In 2021

Biosimilars Business Expands By Over 50%; Sterile Injectables Grow To $5.7bn

 
• By Akriti Seth
  
Growth
Pfizer’s biosimilars business sees double-digit growth • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products